Skip to main content

8 Result(s)

within B. Brado Remove this filter

and

  1. No Access

    Article

    Loss of collagen type IV in rheumatoid synovia and cytokine effect on the collagen type-IV gene expression in fibroblast-like synoviocytes from rheumatoid arthritis

    Collagen type IV is a structural matrix protein which contributes to the structural organization of the synovia. In order to characterize the distribution of this protein in synovia with chronic synovitis, col...

    N. Rinaldi, M. Willhauck, D. Weis, B. Brado, P. Kern, M. Lukoschek… in Virchows Archiv (2001)

  2. No Access

    Article

    Malignant lymphoma. Diagnostic and follow-up in adults

    M. Brado, B. Betsch, B. Brado, G. M. Richter, C. Wunsch, G. Nöldge… in Der Radiologe (1997)

  3. No Access

    Chapter and Conference Paper

    Treatment of Metastatic Melanoma with Interferon-α and Interleukin-2: Significant Improvement with a New Dosing Schedule

    Interleukin-2 (IL-2) has been used since 1984 as a single agent or in combination with lymphokine-activated killer cells [l–4] to treat human malignancies. More recently a combination therapy of interferon-alp...

    U. Keilholz, W. Tilgen, L. Bergmann… in Cytokines in Hemopoiesis, Oncology, and AI… (1992)

  4. No Access

    Chapter and Conference Paper

    Induction Therapy for Acute Myelogenous Leukemia with Idarubicin/Cytosine Arabinoside and Mitoxantrone/Etoposide in “Response-Adapted” Sequence

    With conventional induction chemotherapy 47%–72% of adult patients with acute myelogenous leukemia (AML) achieve complete remission (CR). However, the probability of continuous CR ranges from 8% to 45% at 3 ye...

    R. Haas, A. Schneeweiß, B. Brado, B. Witt, W. Hunstein, F. Del Valle… in Acute Leukemias (1992)

  5. No Access

    Chapter and Conference Paper

    The Interleukin-2 Receptor (CD25 and p75) in Human Monocytes and Macrophages

    Interleukin-2 (IL-2) is secreted by T-cells upon antigen presentation and induces proliferation and activation of lymphocytes. It was also shown to induce monocyte (MO) functions, including tumor cytotoxicity ...

    C. Scheibenbogen, U. Keilholz, M. Richter… in Cytokines in Hemopoiesis, Oncology, and AI… (1992)

  6. No Access

    Chapter and Conference Paper

    Neue Ansätze in der Immuntherapie mit Immunmodulatoren bei Patienten mit metastasierendem Melanom

    Neue Behandlungskonzepte des metastasierenden Melanoms stellen die kombinierte systemische oder regionale Immuntherapie mit Interferon (IFN) und Interleukin (IL 2) und mit Interleukin 2 und Lymphokin-aktiviert...

    W. Tilgen, U. Keilholz, H. Welters, B. Brado, R. Metz, P. Schlag… in Das Maligne Melanom (1991)

  7. No Access

    Chapter and Conference Paper

    Regional Adoptive Immunotherapy for Hepatic Metastasis

    Adoptive immunotherapy has proved to be effective in certain human cancers. To improve the efficacy of this treatment modality, we developed a protocol for regional treatment of hepatic metastasis. A regional ...

    U. Keilholz, B. Brado, P. Schlag, W. Tilgen… in Cytokines in Hemopoiesis, Oncology, and AI… (1990)

  8. No Access

    Chapter

    The Plasmacytoid T Cell or Plasmacytoid Monocyte — A Sessile Lymphoid Cell with Unique Immunophenotype and Unknown Function, Still Awaiting Lineage Affiliation

    Plasmacytoid T cells (PTCs) were first described in 1958, as clusters of cells with the light-microscopic appearance of “lymphoblasts” (Lennert and Remmele 1958). The electron-microscopic features conformed to th...

    B. Brado, P. Möller in Reaction Patterns of the Lymph Node (1990)